Bristol-Myers Squibb EPS (Diluted) increased by 147.2% to $1.31 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.2%, from $1.20 to $1.31. Over 4 years (FY 2021 to FY 2025), EPS (Diluted) shows an upward trend with a 2.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher values indicate stronger profitability even when accounting for potential share dilution.
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Used by all public companies to provide a realistic view of earnings per share for investors.
eps_diluted| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.47 | $0.69 | $1.07 | $0.59 | $0.66 | $0.75 | $0.95 | $1.07 | $0.99 | $0.93 | $0.87 | -$5.89 | $0.83 | $0.60 | $0.00 | $1.20 | $0.64 | $1.08 | $0.53 | $1.31 |
| QoQ Change | — | +46.8% | +55.1% | -44.9% | +11.9% | +13.6% | +26.7% | +12.6% | -7.5% | -6.1% | -6.5% | -777.0% | +114.1% | -27.7% | -100.0% | — | -46.7% | +68.8% | -50.9% | +147.2% |
| YoY Change | — | — | — | — | +40.4% | +8.7% | -11.2% | +81.4% | +50.0% | +24.0% | -8.4% | -650.5% | -16.2% | -35.5% | -100.0% | +120.4% | -22.9% | +80.0% | — | +9.2% |